ProCE Banner Activity

CCO 2022 Global Conference Coverage: Gynecologic Cancer Updates

Slideset Download
Conference Coverage
Download this “living” summary slideset covering new data from key studies in gynecologic cancers as they are presented at different conferences throughout 2022.

Released: November 10, 2022

Expiration: November 09, 2023

Share

Faculty

Susana Banerjee

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Jubilee Brown

Jubilee Brown, MD

Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Elisabeth Diver

Elisabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Angeles Alvarez Secord

Angeles Alvarez Secord, MD, MHSc

Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Jubilee Brown, MD

Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Jubilee Brown, MD: funds for research support: Olympus, Tesaro/GlaxoSmithKline.

Elisabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Elisabeth Diver, MD: consulting fees: EMD Serono, GlaxoSmithKline; funds for research support: Aravive, EMD Serono, GlaxoSmithKline.

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability, AstraZeneca, Clovis, GlaxoSmithKline; Merk Sharp and Dohme, and Zentalis; researcher: AstraZeneca and Apmonia.

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca; Clovis, Genmab, GlaxoSmithKline, Immunogen, Merk Sharp and Dohme, Novartis, Sutro, and Seagen.

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

David Scott Miller, MD, FACOG, FACS, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Eisai, EMD Serono, GlaxoSmithKline, Incyte, iTeos Belgium SA, Myriad Genetics Laboratories, Novocure, Seagen, Tarveda, and Tesaro and funds for research support from Advenchen, Agenus, AKESOBIO Australia PTY, Eisai Europe Limited, EMD Serono, Karyopharm, Merck Sharp & Dohme, Novocure, and Tesaro.

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Angeles Alvarez Secord, MD, MHSc

Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Angeles Alvarez Secord, MD, MHSc, has disclosed that she has received consulting fees from Eisai and Myriad and funds for research support from AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep, Merck, OncoQuest, PharmaMar, Roche/Genentech, Seagen, Tesaro/GlaxoSmithKline, and VBL.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium